Oral Vitamin D Supplementation as Add-On Therapy in Adult Patients with Atopic Dermatitis
DOI:
https://doi.org/10.37275/bsm.v7i12.895Keywords:
Atopic dermatitis, Dietary supplement, Randomized controlled trial, Vitamin DAbstract
Background: Recent studies have highlighted the possible role of vitamin D in atopic dermatitis (AD) so that it can be used as therapeutical of AD. The aim of study to evaluate the effect of vitamin D supplementation as add-on therapy in adult patients with AD.
Methods: Twenty-four adult patients with AD were included in a randomized, double-blind, placebo-controlled trial study. This study was conducted in Dr. Moewardi General Hospital Surakarta, Indonesia, from February to March 2023. Subjects were randomly assigned to oral cholecalciferol 5,000 IU/day versus placebo for 4 weeks and all subjects were given emollient. The severity of AD was evaluated by using scoring of atopic dermatitis (SCORAD) before and after the trial.
Results: Compared to placebo, vitamin D supplementation for 1 month obtained clinically and statistically improvement in SCORAD score compare to control (-4.508 : 4.500, p= 0.000). Moreover, vitamin D supplementation had strong negative correlation to SCORAD score after the trial (r= -0.780, p= 0,000). There were no adverse effects in either group. and
Conclusion: Clinical improvement was achieved after vitamin D supplementation as add-on therapy in adult patients with AD.
Authors
- Bobby Febrianto1*
- Prasetyadi Mawardi1
- Harijono Kariosentono1
- 1Department of Dermatology and Venereology, Faculty of Medicine, Universitas Sebelas Maret/Dr. Moewardi General Hospital, Surakarta, Indonesia
Corresponding author Bobby Febrianto — Bobbyf100289@gmail.com
Article history
- Submitted
- Accepted
- Published
Downloads
Published
Issue
Section
License
Copyright and licensing
Copyright in each article remains with the author(s). Authors grant Bioscientia Medicina: Journal of Biomedicine and Translational Research a non-exclusive right of first publication and the right to identify itself as the original publisher. No exclusive transfer of copyright is required.
All articles are published under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0): https://creativecommons.org/licenses/by-nc-sa/4.0/. Users may copy, redistribute, remix, transform, and build upon the material for non-commercial purposes, provided appropriate attribution is given, a link to the license is supplied, changes are indicated, and adaptations are distributed under the same license.
The license applies to the article's scholarly content unless a credit line states otherwise. Third-party material may be subject to separate rights. Authors retain patent, trademark, moral, and research-data rights. The copyright year follows the article's publication date.
